Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8352
Reference
Drug alert 63/2024
Name
Drug Alert Class 4 Drug Alert 63 2024 – Class 4 medicines defect information – caution in use – Argenx BV – Vygart 1000mg Solution for Injection
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
Scotland
Drugs
Safety
Risks
Pharmaceutical Industry
Medicines Recall
Description
Argenx BV have informed MHRA that the Patient Information Leaflet (PIL) in the affected packs incorrectly contains reference to two subcutaneous injection sites (abdomen and thigh) at Step 20 of the instructions. The correct PIL, approved as part of the GB marketing authorisation, only contains reference to one subcutaneous injection site (abdomen).
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2024-12-19 13:20:24
Click to go back to homepage